Retatrutide's mechanism of action as a triple hormone receptor agonist sets it apart from any currently approved weight management medicine. Developed by Eli Lilly and Company, this investigational injectable peptide simultaneously targets three distinct hormone receptor pathways — GLP-1, GIP, and glucagon — to address appetite, glucose metabolism, and energy expenditure in a single molecule. Early clinical data have generated significant scientific interest, particularly for the treatment of obesity and type 2 diabetes. This article explains how retatrutide works, what the current clinical evidence shows, its potential benefits and risks, and its regulatory status in the United Kingdom as of mid-2025.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational once-weekly injectable peptide that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved single or dual receptor agonists such as semaglutide and tirzepatide.

Retatrutide is an investigational injectable peptide medicine currently under clinical development by Eli Lilly and Company. It belongs to an emerging class of metabolic medicines being studied for the treatment of obesity and type 2 diabetes mellitus by simultaneously targeting three distinct hormone receptor pathways. This multi-receptor approach distinguishes retatrutide from earlier agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1 and GIP receptor agonist).

In Phase 2 clinical trials, retatrutide was administered as a once-weekly subcutaneous injection, consistent with the delivery schedule used for existing approved therapies such as semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®). Its molecular structure is engineered as a single synthetic peptide capable of activating glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors concurrently. This triple agonism is intended to produce complementary effects on appetite regulation, energy expenditure, and glucose metabolism.

The pharmacological rationale behind retatrutide reflects a growing understanding that obesity and metabolic disease involve multiple overlapping hormonal dysregulations. By addressing these pathways simultaneously, retatrutide is hypothesised to achieve greater efficacy in reducing body weight and improving cardiometabolic markers than single or dual receptor agonists. Early phase clinical data have generated considerable scientific interest. However, retatrutide remains an investigational medicinal product and, as of mid-2025, has not been approved for clinical use in the United Kingdom or elsewhere.

Triple Hormone Receptor Agonism: GLP-1, GIP, and Glucagon Pathways

Retatrutide combines GLP-1-mediated appetite suppression and insulin secretion, GIP-enhanced glycaemic benefit, and glucagon receptor-driven energy expenditure and hepatic fat oxidation into a single pharmacological profile.

Understanding retatrutide's proposed mechanism of action requires familiarity with the three hormone receptor systems it engages. It is important to note that whilst GLP-1 receptor agonism is well characterised in approved medicines, some mechanistic claims relating to GIP and glucagon receptor activity in humans are based on preclinical data and early clinical findings, and the relative contribution of each pathway in humans is not yet fully elucidated.

GLP-1 (Glucagon-Like Peptide-1) Receptor Agonism GLP-1 is an incretin hormone secreted by intestinal L-cells in response to food intake. Activation of GLP-1 receptors stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite via central nervous system pathways. These effects collectively lower blood glucose and promote satiety, contributing to weight loss. This mechanism is well established through approved GLP-1 receptor agonists.

GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonism GIP is secreted by intestinal K-cells and also acts as an incretin hormone. GIP receptor activation enhances insulin secretion in a glucose-dependent manner and, based on preclinical and early clinical data, may improve insulin sensitivity in adipose tissue. When combined with GLP-1 receptor agonism, GIP activity appears to amplify weight loss and glycaemic benefits, as suggested by tirzepatide's clinical profile (NICE TA943).

Glucagon Receptor Agonism This is the distinguishing feature of retatrutide compared to existing approved agents. Glucagon, traditionally associated with raising blood glucose, also plays a role in stimulating hepatic fat oxidation and increasing energy expenditure — effects observed in preclinical models and supported by early clinical data. Selective glucagon receptor activation may promote energy expenditure and reduce hepatic steatosis (fatty liver). In the context of concurrent GLP-1 agonism — which is hypothesised to counterbalance glucagon's hyperglycaemic effects — net glucagon receptor stimulation may enhance fat metabolism without causing clinically significant hyperglycaemia. This hypothesis is supported by early trial data but requires confirmation in larger Phase 3 studies.

The integration of all three pathways is proposed to create a complementary pharmacological profile: appetite suppression and improved insulin secretion from GLP-1 and GIP agonism, combined with enhanced energy expenditure and hepatic lipid metabolism from glucagon receptor activation. This mechanistic hypothesis underpins the substantial weight loss signals observed in early trials, though the precise contribution of each receptor pathway in humans remains an active area of investigation.

Clinical Evidence and Ongoing Trials

A 2023 Phase 2 trial in the New England Journal of Medicine reported approximately 24% mean body weight reduction at 48 weeks with the 12 mg dose; Phase 3 TRIUMPH trials are now underway internationally.

The most significant clinical data for retatrutide to date come from a Phase 2 randomised, double-blind, placebo-controlled trial published in The New England Journal of Medicine in 2023. This study enrolled adults with obesity (body mass index ≥30 kg/m²) without type 2 diabetes, and a separate cohort with type 2 diabetes, across multiple international sites.

In the non-diabetes cohort, participants receiving the highest dose of retatrutide (12 mg weekly) achieved a mean body weight reduction of approximately 24% over 48 weeks — a figure that substantially exceeds weight loss outcomes reported with currently approved agents at comparable timepoints. In the type 2 diabetes cohort, retatrutide also produced clinically meaningful weight loss alongside reductions in HbA1c. Across both cohorts, the trial demonstrated improvements in cardiometabolic parameters including reductions in waist circumference, blood pressure, triglycerides, and fasting glucose.

Phase 3 clinical trials — collectively referred to as the TRIUMPH programme — are now underway internationally, evaluating retatrutide across broader populations including individuals with type 2 diabetes, obesity-related cardiovascular disease, and metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH). Patients interested in trial participation should speak with their GP or specialist. Information on trials currently recruiting in the UK can be found via the NIHR Be Part of Research platform (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov.

It is important to note that Phase 2 data, whilst promising, do not yet constitute the full evidence base required for regulatory approval. Longer-term safety and efficacy data from Phase 3 trials are essential before any licensing decision can be made.

Potential Benefits, Risks, and Side Effects

Potential benefits include improved glycaemic control and reduced cardiovascular risk factors; the most common side effects are gastrointestinal, including nausea, vomiting, and diarrhoea, consistent with the GLP-1 receptor agonist class.

Based on Phase 2 trial data, retatrutide has demonstrated a number of potential benefits. The most notable is its capacity for substantial weight reduction, which may in turn confer downstream benefits including:

• Improved glycaemic control in individuals with type 2 diabetes

• Reduced cardiovascular risk factors such as hypertension and dyslipidaemia

• Potential improvement in hepatic steatosis, given the glucagon receptor component's proposed role in hepatic fat metabolism

• Possible improvements in physical function and quality of life associated with significant weight loss — though these outcomes have not yet been formally established for retatrutide and require confirmation in Phase 3 trials

As with all medicines in this class, retatrutide carries a recognised side effect profile. The most commonly reported adverse effects in Phase 2 trials were gastrointestinal in nature, including:

• Nausea (the most frequently reported)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

These effects were generally dose-dependent and most pronounced during dose escalation, typically improving over time. They are consistent with the known side effect profile of GLP-1 receptor agonists already approved in the UK (see, for example, the Wegovy® Summary of Product Characteristics, available via the electronic Medicines Compendium).

Gallbladder disease: As with other medicines in this class, there is a potential risk of gallbladder-related complications, including gallstones (cholelithiasis) and cholecystitis. Patients should seek prompt medical attention if they experience right upper quadrant pain, fever, or jaundice.

Hypoglycaemia: As monotherapy, the risk of hypoglycaemia with retatrutide is expected to be low, given its glucose-dependent mechanism of action. However, the risk may increase if used alongside insulin or sulfonylureas; any such combination would require careful clinical review and possible dose adjustment of concomitant medicines.

Dehydration and kidney function: Prolonged vomiting or diarrhoea can lead to dehydration and, in some cases, acute kidney injury. Patients should maintain adequate fluid intake and seek urgent medical attention if they are unable to keep fluids down.

Pancreatitis: Anyone experiencing persistent severe abdominal pain, particularly if radiating to the back, should seek urgent medical attention, as this may indicate pancreatitis — a recognised risk with incretin-based therapies.

The addition of glucagon receptor agonism introduces further safety considerations requiring evaluation in Phase 3 trials, including potential effects on heart rate, blood pressure, and hepatic glucose output.

Thyroid C-cell effects: Preclinical studies with GLP-1 receptor agonists have identified thyroid C-cell changes in rodents; the clinical relevance in humans remains uncertain. In clinical trials of this drug class, individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) are typically excluded as a precautionary measure. This reflects trial eligibility criteria rather than a formal contraindication in UK prescribing labelling for currently licensed GLP-1 receptor agonists.

Any suspected side effects from medicines — including those experienced during clinical trials — should be reported via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Current Regulatory Status and Availability in the UK

Retatrutide has not received MHRA marketing authorisation as of mid-2025 and is unavailable for prescription in the UK outside approved clinical trials; NHS availability would require both MHRA approval and a positive NICE technology appraisal.

As of mid-2025, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). It remains an investigational medicinal product (IMP) and is therefore not available for prescription or purchase in the United Kingdom outside of approved clinical trials.

The MHRA is the medicines regulator for the whole of the United Kingdom, including Northern Ireland, following the implementation of the Windsor Framework for medicines (from 1 January 2025). The MHRA will be responsible for evaluating any future marketing authorisation application for retatrutide across the UK. Comprehensive Phase 3 safety and efficacy data are required before a licensing decision can be considered.

Patients and healthcare professionals should exercise caution regarding unregulated sources. There is a growing and concerning market for unlicensed weight loss injectables in the UK, and obtaining any unregulated injectable product outside of a legitimate clinical or prescribing setting carries serious safety risks, including the risk of counterfeit or substandard products. The MHRA and Trading Standards have issued alerts regarding unauthorised weight loss pens. Patients should only obtain medicines from pharmacies registered with the General Pharmaceutical Council (GPhC).

Following any MHRA marketing authorisation, NICE (the National Institute for Health and Care Excellence) would be expected to conduct a technology appraisal to determine whether retatrutide represents a cost-effective use of NHS resources and to establish guidance on appropriate patient populations. NHS commissioning of retatrutide would depend on the outcome of such an appraisal. Until that point, retatrutide will not be routinely available through the NHS.

Patients seeking support for obesity management in the meantime should speak with their GP, who can refer to NHS Tier 3 weight management services (in line with NICE CG189) or consider currently approved pharmacological options where clinically appropriate.

Frequently Asked Questions